Levobupivacaine Medac (Levobupivacaine)

Levobupivacaine works by reversibly inhibiting voltage‑gated sodium channels on neuronal membranes. This blockade prevents the initiation and propagation of nerve impulses, resulting in a loss of sensation in the targeted area while preserving motor function at appropriate concentrations.

The specific dose of Levobupivacaine Medac is determined by the prescribing clinician based on the type of procedure, patient characteristics, and route of administration. Healthcare professionals adjust the volume and concentration to achieve the desired anesthetic effect.

Safety data for Levobupivacaine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is typically administered under specialist supervision.

To order Levobupivacaine Medac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine, offering a similar duration of anesthesia with a reduced risk of cardiotoxicity and central nervous system toxicity. This safety profile makes it a preferred option when prolonged block is needed, especially in patients with cardiovascular concerns.

Levobupivacaine Medac should be stored at controlled room temperature, typically below 25 °C, in its original packaging. Protect the solution from direct light and moisture, and avoid freezing. Follow local regulations for handling sterile injectable solutions.

Levobupivacaine is administered by a qualified healthcare professional via epidural, infiltration, or intrathecal injection. The sterile solution is injected into the appropriate anatomical space using aseptic technique, with dosage and concentration tailored to the specific clinical indication.

Serious risks include cardiac arrhythmias, seizures, prolonged motor block, severe allergic reactions, respiratory depression, and methemoglobinemia. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after administration.

Levobupivacaine should be avoided in individuals with known hypersensitivity to amide‑type local anesthetics, severe cardiac conduction disorders, or uncontrolled epilepsy. Caution is also advised for patients with significant hepatic impairment or those receiving other potent local anesthetics.